Savolitinib

Generic Name: Savolitinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₅N_₉

CAS Number: 1313725-88-0

Unique Ingredient Identifier: 2A2DA6857R

Background: Savolitinib has been used in trials studying the treatment and health services research of Tumor, Food Effect, Gastric Cancer, Health Subjects, and Colorectal Cancer, among others.

Indication: 用于含铂化疗后疾病进展或不耐受标准含铂化疗的、具有间质-上皮转化因子（MET）外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Phase 2

Active, not recruiting

Conditions: Carcinoma

Interventions: Drug: savolitinib
Drug: osimertinib
Drug: placebo

First Posted Date: 2018-12-19

Last Posted Date: 2024-07-05

Lead Sponsor: AstraZeneca

Target Recruit Count: 366

Registration Number: NCT03778229

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

Phase 1

Recruiting

Conditions: Refractory Primary Central Nervous System Neoplasm
Recurrent Diffuse Intrinsic Pontine Glioma
Recurrent Malignant Glioma
Recurrent Medulloblastoma
Recurrent Primary Central Nervous System Neoplasm
Refractory Diffuse Intrinsic Pontine Glioma
Refractory Malignant Glioma
Refractory Medulloblastoma

Interventions: Procedure: Biospecimen Collection
Procedure: Magnetic Resonance Imaging
Drug: Savolitinib
Procedure: X-Ray Imaging

First Posted Date: 2018-07-26

Last Posted Date: 2024-11-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT03598244

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 9 locations

Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer

Phase 2

Terminated

Conditions: Stage IIIB Colon Cancer AJCC v8
Stage IIIC Colon Cancer AJCC v8
Stage IVB Colon Cancer AJCC v8
Metastatic Rectal Adenocarcinoma
Stage III Colon Cancer AJCC v8
Stage IVA Colon Cancer AJCC v8
Stage IVC Colon Cancer AJCC v8
Stage IVC Rectal Cancer AJCC v8
Unresectable Rectal Adenocarcinoma
Stage IIIC Rectal Cancer AJCC v8

Interventions: Drug: Savolitinib

First Posted Date: 2018-07-19

Last Posted Date: 2023-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT03592641

Locations: 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 30 locations

Prostate Cancer Biomarker Enrichment and Treatment Selection

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Savolitinib
Drug: Darolutamide
Drug: CFI-400945
Drug: Durvalumab and Tremelimumab
Drug: Adavosertib
Drug: Ipatasertib
Drug: Carboplatin

First Posted Date: 2017-12-28

Last Posted Date: 2024-02-29

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 200

Registration Number: NCT03385655

Locations: 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

and more 8 locations

Savolitinib vs. Sunitinib in MET-driven PRCC.

Phase 3

Active, not recruiting

Conditions: Protein Kinase Inhibitors
Carcinoma
Carcinoma, Renal Cell
Enzyme Inhibitors
Urologic Neoplasms
Kidney Diseases
Kidney Neoplasms
Neoplasms by Site

Interventions: Drug: Sunitinib
Drug: Savolitinib

First Posted Date: 2017-03-27

Last Posted Date: 2024-10-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 60

Registration Number: NCT03091192

Locations: 🇺🇦
Research Site, Sumy, Ukraine

A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer

Phase 2

Conditions: Lung Sarcomatoid Carcinoma

Interventions: Drug: Savolitinib

First Posted Date: 2016-09-13

Last Posted Date: 2021-11-30

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 76

Registration Number: NCT02897479

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
🇨🇳
Beijing Cancer Hopspital, Beijing, Beijing, China

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma

Phase 2

Completed

Conditions: Renal Clear Cell Carcinoma
Renal Papillary Cell Carcinoma

Interventions: Drug: Savolitinib
Drug: MEDI4736
Drug: Tremelimumab

First Posted Date: 2016-06-30

Last Posted Date: 2024-11-04

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 69

Registration Number: NCT02819596

Locations: 🇬🇧
Thomas Powles, London, United Kingdom

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Phase 2

Active, not recruiting

Conditions: Locally Advanced Papillary Renal Cell Carcinoma
Metastatic Papillary Renal Cell Carcinoma
Type 1 Papillary Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v7
Stage III Renal Cell Cancer AJCC v7
Unresectable Renal Cell Carcinoma
Type 2 Papillary Renal Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Scan
Drug: Cabozantinib S-malate
Procedure: Computed Tomography
Drug: Sunitinib Malate
Drug: Crizotinib
Drug: Savolitinib

First Posted Date: 2016-05-04

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 152

Registration Number: NCT02761057

Locations: 🇺🇸
Pali Momi Medical Center, 'Aiea, Hawaii, United States
🇺🇸
Queen's Cancer Center - Pearlridge, 'Aiea, Hawaii, United States
🇺🇸
Illinois CancerCare-Peru, Peru, Illinois, United States

and more 593 locations

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

Phase 2

Completed

Conditions: Advanced Gastric Adenocarcinoma

Interventions: Drug: Volitinib

First Posted Date: 2015-05-20

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 16

Registration Number: NCT02449551

Locations: 🇰🇷
Samsung Medical center, Seoul, Korea, Republic of

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Volitinib
Drug: gefitinib

First Posted Date: 2015-03-02

Last Posted Date: 2020-04-24

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 64

Registration Number: NCT02374645

Locations: 🇨🇳
Guangdong General Hospital, Guangzhou, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy